research use only

Ticarcillin sodium Selection Antibiotics for Transfected Cell inhibitor

Name: Ticarcillin sodium
Brand: Selleck Chemicals
SKU: S3193
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S3193

Ticarcillin (AB 2288, BRL 2288) is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria.

Chemical Structure

Molecular Weight: 430.41

Jump to

Quality Control

Batch: Purity: 98.61%

98.61

Related Targets	Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV
Other Selection Antibiotics for Transfected Cell Inhibitors	Blasticidin S Hydrochloride Ribostamycin Sulfate D-Cycloserine

Solubility

In vitro
Batch:

DMSO : 86 mg/mL (199.8 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 86 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	430.41	Formula	C₁₅H₁₆N₂O₆S₂.2Na	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	29457-07-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	AB 2288, BRL 2288			Smiles	CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CSC=C3)C(=O)[O-])C(=O)[O-])C.[Na+].[Na+]

Mechanism of Action

In vitro	MICs of Ticarcillin (64 mg/mL) for 90% of all beta-lactamase-positive strains are reduced to 2 mg/mL, with the addition of clavulanate. MICs of Ticarcillin for 90% of all beta-lactamase-negative strains are 4 mg/mL. 93.4% of the beta-lactamase-producing strains are susceptible to Ticarcillin at less than or equal to 64 mg/mL. Ticarcillin/potassium clavulanate is light stable and resistant to inactivation by β-lactamase. Ticarcillin/potassium clavulanate is more economical than carbenicillin and cefotaxime to eliminate Agrobacterium tumefaciens in plant transformation.
In vivo	The mean elimination half-life of Ticarcillin (120 mg/kg) in serum is 70.8 minutes in the control subjects and 53.1 minutes in the patients with cystic fibrosis. The total body clearance of Ticarcillin is significantly higher in cystic fibrosis patients (65.6 mL/min/m2 versus 46.2 mL/min/m2 in control subjects). The nonrenal clearance of ticarcillin is also significantly higher in patients with cystic fibrosis (24.8 mL/min/m2 versus 13.3 mL/min/m2 for the control group). Ticarcillin/clavulanate (3.1g, given iv every 4-6 hours) results in clinical success rate of 80.3% and clinical failure rate of 19.7% in the treatment of complicated skin and skin-structure infections. The overall rate of eradication is 83.7% in the Ticarcillin/clavulanate treatment group in the microbiologically evaluable population. Ticarcillin/clavulanate results in cure rates of 79% at the time of final assessment for the treatment of intra-abdominal infections in pediatric and adult patients.
References	[1] https://pubmed.ncbi.nlm.nih.gov/2221864/ [2] http://link.springer.com/article/10.1007%2Fs002990050495?LI=true# [3] https://pubmed.ncbi.nlm.nih.gov/2295222/ [4] https://pubmed.ncbi.nlm.nih.gov/12145720/ [5] https://pubmed.ncbi.nlm.nih.gov/7893090/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01229046	Withdrawn	Sepsis	Phillip Brian Smith\|Duke University	September 2010	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):